@article{10.11648/j.cmr.20231204.11,
  author = {Yanqing Song and Rui Zhou},
  title = {The Use of Esketamine in Clinical Anesthesia Practice},
  journal = {Clinical Medicine Research},
  volume = {12},
  number = {4},
  pages = {61-64},
  doi = {10.11648/j.cmr.20231204.11},
  url = {https://doi.org/10.11648/j.cmr.20231204.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20231204.11},
  abstract = {Esketamine, a new noncompetitive antagonist of the N-Methyl-D-Aspartate (NMDA) receptor, has been approved by Food and Drug Administration of the United States of America and recently permitted to apply in Chinese medical institutions. By binding to NMDA receptor, esketamine exerts analgesic, sedative and antidepressant effects with no suppression of respiratory and circulatory system, which is similar to ketamine. However, as the right hand enantiomer of ketamine, esketamine shows higher efficiency, which means that a lower dose can exert comparable effects of ketamine. Meanwhile, the security of esketamine is higher due to less severe adverse events observed in preliminary clinical trials. With more advantages and less disadvantages, anesthesiologists have attached much attention to esketamine. Previous studies have explored the applications of esketamine in clinical practice, such as pediatric anesthesia, painless endoscopy, intubation or non-intubation surgery. These studies focused on the dosage, effectiveness, merits and demerits under different circumstances. In this review, we retrospected recent clinical trials, summarized the efficiency and safety of esketamine by classification of applying scenarios. Either anesthetic or subanesthetic dosage, bolus or continuous infusion made a significance in perioperative management. We also promoted some promising applications of esketamine in anesthesia. However, these novel ideas need more high-quality trials to reconfirm. Anyway, esketamine is a superior choice for anesthesiologists.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - The Use of Esketamine in Clinical Anesthesia Practice
AU  - Yanqing Song
AU  - Rui Zhou
Y1  - 2023/07/06
PY  - 2023
N1  - https://doi.org/10.11648/j.cmr.20231204.11
DO  - 10.11648/j.cmr.20231204.11
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 61
EP  - 64
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20231204.11
AB  - Esketamine, a new noncompetitive antagonist of the N-Methyl-D-Aspartate (NMDA) receptor, has been approved by Food and Drug Administration of the United States of America and recently permitted to apply in Chinese medical institutions. By binding to NMDA receptor, esketamine exerts analgesic, sedative and antidepressant effects with no suppression of respiratory and circulatory system, which is similar to ketamine. However, as the right hand enantiomer of ketamine, esketamine shows higher efficiency, which means that a lower dose can exert comparable effects of ketamine. Meanwhile, the security of esketamine is higher due to less severe adverse events observed in preliminary clinical trials. With more advantages and less disadvantages, anesthesiologists have attached much attention to esketamine. Previous studies have explored the applications of esketamine in clinical practice, such as pediatric anesthesia, painless endoscopy, intubation or non-intubation surgery. These studies focused on the dosage, effectiveness, merits and demerits under different circumstances. In this review, we retrospected recent clinical trials, summarized the efficiency and safety of esketamine by classification of applying scenarios. Either anesthetic or subanesthetic dosage, bolus or continuous infusion made a significance in perioperative management. We also promoted some promising applications of esketamine in anesthesia. However, these novel ideas need more high-quality trials to reconfirm. Anyway, esketamine is a superior choice for anesthesiologists.
VL  - 12
IS  - 4
ER  - 

Copy | Download